Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedSV
Sanofi Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026
- Rounds participated in
- 5
- Confirmed lead rounds
- — 5 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $391M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionQuantHealth
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment
$45MSeries B
Role not disclosedDraig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedBionyra Pharma
Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases.
$165MSeries A
Role not disclosedBranchLab
Builds AI platform helping pharma companies identify, activate and optimize patient and HCP audiences
$26MSeries A
Role not disclosed